Core Insights - The company reported annual revenue of approximately RMB 700 million to 720 million for the period ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% [1] Group 1: Revenue Growth - The continuous revenue growth is primarily attributed to the strong performance of all three major product lines in the neurointervention business and the expanding market share in the transcatheter aortic valve replacement (TAVR) market, driven by the successful launch of the high-end TaurusMax® 3D adjustable TAVR system [1] - All three major product lines in neurointervention recorded robust revenue growth, reflecting strong performance of their core products [1] Group 2: Product Performance - The vascular access products saw revenue growth, benefiting from the increasing sales of the high-performance DCwire® microcatheter, which significantly enhanced market share [1] - The hemorrhagic product line experienced revenue growth due to the successful launch of the YonFlow® flow-directed mesh stent [1] - The ischemic product line's revenue growth was mainly driven by increased sales of the Syphonet® thrombectomy stent and Tethys AS® thrombectomy catheter [1] Group 3: TAVR Market Expansion - The commercialized TAVR product portfolio was adopted in approximately 130 new hospitals during the reporting period, covering over 780 hospitals as of December 31, 2025 [2] - A total of approximately 3,900 units were implanted during the reporting period, representing a year-on-year growth of 14.4%, significantly exceeding the overall market growth rate [2] - The company anticipates full commercialization in the Chinese aortic regurgitation market following the approval of the registration application for the TaurusTrio® transcatheter aortic valve system by the National Medical Products Administration in December 2025 [2]

Core Viewpoint - The company, Peijia Medical-B (09996.HK), anticipates a revenue of approximately RMB 700 million to RMB 720 million for the fiscal year ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% compared to RMB 615.5 million in 2024, driven by strong performance across its neurointerventional product lines and an expanding market share in the TAVR segment [1]. Group 1: Revenue Growth Drivers - The neurointerventional business has shown robust revenue growth across all three product lines, reflecting strong performance of core products [2]. - Revenue growth in vascular access products is primarily attributed to the increasing sales of the high-performance DCwire® microcatheter, which has significantly enhanced market share [2]. - The hemorrhagic products segment has benefited from the successful launch of the YonFlow® flow-directed stent, contributing to revenue growth in this product line [2]. - Revenue growth in ischemic products is mainly due to increased sales of the Syphonet® thrombectomy stent and Tethys AS® thrombectomy catheter, with overall revenue stability despite price reductions following the implementation of volume-based procurement [2]. Group 2: TAVR Market Expansion - The company's commercialized TAVR product portfolio, including TaurusOne®, TaurusElite®, and TaurusMax® systems, has been adopted by approximately 130 new hospitals, reaching a total of over 780 hospitals by December 31, 2025 [2]. - A total of approximately 3,900 TAVR procedures were implanted during the reporting period, marking a year-on-year growth of 14.4%, significantly outpacing the overall market growth rate [3]. - The company expects to fully commercialize the TaurusTrio® transcatheter aortic valve system in the Chinese aortic regurgitation market following its approval by the National Medical Products Administration in December 2025 [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Peijia Medical Limited 沛嘉醫療有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9996） 自願性公告 截至2025年12月31日止年度的未經審核營運數據 本公告由沛嘉醫療有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以向本公司股東及潛在投資者提供有關本集團最新業務及產品開發進 展的最新資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈本集團截至2025年12月31日止年度 （「報告期間」）的若干未經審核營運數據及比較數據載列如下。 1月1日至12月31日期間 | 2025年 | 2024年 | 變動 | | --- | --- | --- | | 人民幣百萬元 | 人民幣百萬元 | % | – 1 – 神經介入所有三大產品線均錄得穩健的收入增長，反映其各自核心產品的強 勁表現。主要驅動因素概述如下： 於報告期間，本 ...

Core Viewpoint - North Chip Life Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking the first successful listing of an innovative medical device company under the "fifth set of standards" [1][2] Company Overview - North Chip Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [1][3] - The company was founded in December 2015 by Song Liang, who has over 18 years of experience in advanced medical imaging technology and cardiovascular interventional device development [2][3] Financial Performance - The company has experienced significant revenue growth, with projected revenues of 520 million to 560 million yuan in 2025, representing a year-on-year increase of 64.24% to 76.88% [5] - The net profit for 2025 is expected to be between 78 million and 88 million yuan, marking a turnaround from previous losses [5] - The company raised a total of 999 million yuan in its IPO, with a net amount of 899 million yuan allocated primarily for the construction of an interventional medical device industrial base and R&D [5] Product Development and Market Position - North Chip Life has launched 11 products to the market and has 6 products in development, with its core IVUS and FFR systems having received special review and approval from national authorities [3][4] - The IVUS system is the first domestically approved 60MHz high-speed IVUS product and has captured a significant market share, while the FFR system holds a 30.6% share of the domestic market [4][5] R&D Investment - The company has consistently increased its R&D investment, totaling 389 million yuan over the past three years, with a workforce of 100 R&D personnel, over 40% of whom hold advanced degrees [3][5] Market Trends and Growth Potential - The domestic market for IVUS is expected to grow significantly, with projections indicating a compound annual growth rate of approximately 19.4% from 2024 to 2030 [8] - The overall market for precision-guided percutaneous coronary intervention (PCI) is anticipated to grow from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, with IVUS and FFR systems expected to dominate this market [8] Competitive Landscape - North Chip Life faces competition from established international firms and other domestic manufacturers in the IVUS and FFR markets, which may impact its market share and pricing strategies [7][8] - The company is also subject to pressures from national procurement policies that could affect pricing and market dynamics [7][8]

Core Insights - The article highlights the development of a portable cerebral hemorrhage detection and analysis device by Anying Technology, which aims to significantly reduce the rescue time for stroke patients [1][2] - The project has benefited from a series of innovative policies in Xiong'an New Area, facilitating rapid development and integration of technology [2] Group 1: Company Overview - Anying Technology, founded by Zhou Haoran, is focused on creating a portable medical device that can be easily carried by emergency personnel to assist in timely patient care [1] - The device is currently undergoing further research and clinical testing at Beijing Tiantan Hospital, in collaboration with a multidisciplinary team from top institutions [1] Group 2: Industry Context - The rapid implementation and advancement of the project are attributed to the supportive innovation and entrepreneurship policies in Xiong'an New Area, which have fostered a conducive environment for technological breakthroughs [2] - Anying Technology's success exemplifies the synergistic effect of Xiong'an New Area's "smart" manufacturing ecosystem, which includes partnerships with universities and the establishment of research teams [2]

Core Viewpoint - The Central Cyberspace Administration of China, in collaboration with the National Healthcare Security Administration, is actively addressing false and misleading information related to centralized drug procurement, taking legal actions against accounts that spread anxiety and misinformation [1] Group 1: False Information and Misinformation - Accounts have been identified that fabricate false information regarding the quality of drugs and medical supplies involved in centralized procurement, aiming to attract traffic [1] - Some accounts distort national policies and create false narratives to incite public anxiety regarding original and generic drugs, leading to the promotion of health products and high-end medical insurance [1] - There are instances where non-procurement products are deliberately associated with procurement to mislead the public, damaging the credibility of the procurement process [1]

转自：成都日报锦观 天府中药城进军医疗器械产业新领域 本报讯 （成都日报锦观新闻记者 袁弘） 记者昨日获悉，彭州经开区企业艾立本科技完成A+轮融资， 加速提高全国产超高效液相色谱三重四极杆质谱联用仪市占率。这也成为2026年彭州经开区抢滩万亿医 疗器械新版图的"首作"。 作为四川省专精特新企业、国家级高新技术企业，艾立本科技此次完成的数千万元人民币A+轮融资， 由四川产业基金川创投交子梧桐基金领投，老股东四川发展彭州全球生物医药基金跟投。本轮融资资金 将主要用于艾立本自主正向研制的超高效液相色谱三重四极杆质谱联用仪的产能提升、市场推广及产品 升级等方面工作。 "面对全国园区在生命科学领域的同质化竞争，单纯的规模扩张已经难以持续，彭州经开区正将深厚的 中医药产业底蕴转化为在高端医疗器械赛道上的独特竞争力。彭州经开区相关负责人表示，通过构 建"研发—制造—应用"闭环，深化"药+械+数"融合发展，园区目前已经形成了以"中医诊疗设备、中药 源性医疗器械、智慧健康服务"为特色的产业生态，走出了一条兼具中药基因、彭州特色的医疗器械产 业发展之路。 ...

Core Insights - The National Medical Products Administration (NMPA) is focusing on supporting the innovative development of the biomanufacturing industry during the 14th Five-Year Plan period, transitioning from "follow-up innovation" to "systematic innovation" and from "scale-speed growth" to "quality-efficiency growth" [1] - In 2025, China approved 76 innovative drugs, showcasing its leading position in global R&D applications, with a trend towards complex frontier technologies, diversified innovation entities, and internationalized regulatory standards [1] - The medical device sector is also experiencing strong innovation, with 76 innovative medical devices approved in 2025, a 17% year-on-year increase, and a significant rise in priority approvals [1] Industry Developments - In 2026, the NMPA plans to strengthen drug safety risk management by enhancing risk prevention mechanisms and regulatory oversight across the entire drug clinical trial chain [2] - The focus will be on encouraging innovation while managing risks, particularly in the development of urgently needed drugs and the implementation of drug trial data protection systems [2] - The NMPA aims to improve the quality and efficiency of generic drug evaluations and strengthen post-marketing management of generic drugs [2] Regulatory Enhancements - The NMPA will enhance supervision of online drug sales and improve the drug information traceability system to increase risk management efficiency [2] - Specific attention will be given to new drug targets, AI-driven drug development, and cell and gene therapies, with expedited approval channels to accelerate the market entry of new and effective drugs [2]

Group 1 - The core point of the news is that southbound funds have been reducing their holdings in Qiming Medical-B (02500.HK), with a total net reduction of 97,000 shares over the last five trading days and 753,500 shares over the last twenty trading days [1][2] - As of February 5, 2026, southbound funds hold 52,175,600 shares of Qiming Medical-B, which accounts for 11.82% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show a consistent trend of reduction, with a decrease of 22,000 shares on February 5, 2026, and smaller reductions on previous trading days [2] Group 2 - Qiming Medical Co., Ltd. specializes in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices for treating heart valve diseases [2] - The company's product line includes devices for aortic, pulmonary, mitral, and tricuspid valve interventions, as well as systems for treating hypertrophic cardiomyopathy and renal denervation [2] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, and TriGUARD3 embolic protection device [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Spring Medical (01858.HK) by 153,800 shares on February 5, 2026, marking a decrease of 0.37% [1][2] - Over the past five trading days, there have been three days of net reductions by southbound funds, totaling 427,300 shares [1] - In the last twenty trading days, there were eleven days of net reductions, amounting to 2,033,000 shares [1] Group 2 - As of now, southbound funds hold 41,678,300 shares of Spring Medical, which represents 43.79% of the company's total issued ordinary shares [1] - Spring Medical is primarily engaged in the research, development, production, and sales of implantable orthopedic medical devices, including joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [2] - The company's joint prosthetic products cover major human joints such as the hip, knee, shoulder, and elbow, and its products are sold in both domestic and international markets [2]